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Progranulin (GRN) mutations cause frontotemporal
dementia (FTD), but GRN’s function in the CNS
remains largely unknown. To identify the pathways
downstream of GRN, we used weighted gene coex-
pression network analysis (WGCNA) to develop
a systems-level view of transcriptional alterations in
a human neural progenitor model of GRN-deficiency.
This highlighted key pathways such as apoptosis
and ubiquitination in GRN deficient human neurons,
while revealing an unexpected major role for the
Wnt signaling pathway, which was confirmed by
analysis of gene expression data from postmortem
FTD brain. Furthermore, we observed that the Wnt
receptor Fzd2 was one of only a few genes upregu-
lated at 6 weeks in a GRN knockout mouse, and
that FZD2 reduction caused increased apoptosis,
while its upregulation promoted neuronal survival
in vitro. Together, these in vitro and in vivo data point
to an adaptive role for altered Wnt signaling in GRN
deficiency-mediated FTD, representing a potential
therapeutic target.
INTRODUCTION
Frontotemporal dementia (FTD), the second most common
cause of presenile dementia (Ratnavalli et al., 2002), is also highly
heritable (Chow et al., 1999; Rohrer et al., 2009). Several classes
of dominant causal mutations have been identified in the genes
forMAPT,CHMP2B, and most recently,GRN (Baker et al., 2006;
Cruts et al., 2006), which codes for the protein progranulin1030 Neuron 71, 1030–1042, September 22, 2011 ª2011 Elsevier Inc(GRN). The pathology of GRN+ FTD is characterized by ubiquitin
positive TDP-43 inclusions and absence of t pathology (Eriksen
and Mackenzie, 2008; Josephs et al., 2007; Mackenzie et al.,
2006; Neumann et al., 2006). GRN mutations are dominantly
inherited and the disease mechanism is postulated to be
haploinsufficiency (Ahmed et al., 2007; Cruts and Van Broeck-
hoven, 2008), as most GRN mutations lead to an approximately
50% reduction in GRN levels (Baker et al., 2006; Coppola et al.,
2008; Cruts et al., 2006).
Unlike MAPT, GRN’s role in CNS function was previously not
well-recognized prior to the identification of mutations in the
GRN gene.GRN was not a candidate gene based on hypothesis
driven work; it was found following exhaustive search by classic
positional cloning following linkage (Baker et al., 2006; Cruts
et al., 2006). GRN was first identified as a gene that was overex-
pressed in epithelial tumors and it was further found to be
a player in wound healing and inflammation (Zhu et al., 2002).
Progranulin and granulins have been known to function as
growth factors, exerting opposing effects on cell growth and
neurite outgrowth (Van Damme et al., 2008). But the function of
GRN in the CNS is poorly understood and it has only been
sparsely studied (Neumann et al., 2009; Rohrer et al., 2009).
Given its previously unknown role in neurodegenerative
processes and disease, a broader understanding of its function
in the nervous system would be of great value as a starting point
for future therapeutic development.
Here we use a step-wise approach to gain a systems level
view of the molecular consequences of GRN deficiency. Given
the neuronal specificity of GRN deficiency, we developed an
inducible in vitro model of GRN haploinsufficiency using shRNA
in primary human neural progenitor cells (hNPCs) (Svendsen
et al., 1998) and their differentiated progeny to faithfully model
GRN deficiency. We next performed genome-wide transcrip-
tome analysis to provide an unbiased and broad view of path-
ways directly downstream of GRN loss. By applying weighted.
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Figure 1. An In Vitro Model of GRNDeficiency Using shRNA in NHNP
Cells
(A) Bright-field and fluorescent images of the NHNP cells before and after
differentiation in the presence of doxycycline. hNPCs were infected, selected
with puromycin for 2 weeks, then differentiated for 4 weeks. Expression of
hairpin was verified by visualization of robust RFP expression. No leakage of
the inducible promoter is visible.
(B) Confirmation of GRN knockdown by western blot. Protein was extracted
from the same samples on which the arrays were run. Only one band was
observed for GRN and for b-actin.
(C) Differential expression analysis was carried out and we observed hundreds
of genes changing. Genes were determined to be changing only if they were
differentially expressed in the overlap of both GRN hairpins versus control.
Using the strict criterion of p < 0.005 and computing this for both hairpins
individually against control, the overlap contains 153 genes (hypergeometric
probability = 10E-67). Depicted here is the heat map of all samples for these
153 genes. Most genes (152/153) common to both hairpins are differentially
expressed in the same direction relative to controls, further confirming that this
list of genes is robustly related to GRN knockdown. See also Figure S1, Fig-
ure S2, and Table S1.
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the network structure of acutely dysregulated genes down-
stream of GRN loss. We validate the in vitro results using expres-
sion data from postmortem FTD brain, identifying Wnt signaling
as one of the major signaling pathways altered both during acute
GRN loss in cell culture, and in human brain samples from
patients with GRN mutations (GRN+). Functional analysis in
human neural progenitors confirmed the predicted relationship
between altered Wnt signaling and apoptosis observed in vitro.
These data suggest that the proapoptotic effect of GRN knock-
down may be mitigated by an alteration in Wnt signaling, which
may represent a possible target for treatment of FTD.
RESULTS
GRN Knockdown in Human Neural Progenitors
and Progeny
The major effect of GRN deficiency in humans primarily involves
the loss of neurons, despite nearly ubiquitous GRN expression in
most cells and tissues (Daniel et al., 2000). We therefore devel-
oped an in vitro model of GRN deficiency using primary human
neural stem cells in which shRNA was used to diminish GRN
levels by at least 50%, as is observed in cells from patients
with GRN mutations (Baker et al., 2006; Cruts et al., 2006; Finch
et al., 2009; Ghidoni et al., 2008). We observed robust gene
expression changes with GRN knockdown, including enrich-
ment of gene ontology categories pertaining to the cell cycle
and ubiquitination (see Table S1 available online). This was
encouraging, given the presence of ubiquitinated inclusions
including TDP-43 as a major pathological feature in patient
brains (Liu-Yesucevitz et al., 2010; Neumann et al., 2006).
However, we also observed that viral infection itself (Supple-
mental Experimental Procedures) led to acute changes in GRN
levels, consistent with its upregulation during the acute phase
of inflammation (Guerra et al., 2007; He et al., 2003). So, to avoid
the potential confound of the acute GRN changes associated
with infection, we developed a tetracycline inducible system
(Gossen and Bujard, 1992) that enables the study of GRN loss
in NHNPs during proliferation, differentiation, and postdifferen-
tiation. To control for off-target effects, two hairpins against
GRN were used, and a scrambled hairpin was used as a control.
hNPC expression of shRNA was verified by robust RFP
expression (Figure 1A). GRN knockdown was confirmed by
western blotting (Figure 1B), and at the RNA level via analysis
of the GRN probes on the microarray (Figure S1). The two GRN
probes on the array demonstrated robust and statistically signif-
icant knockdown (60%–74%, p < 10E-6). Although the two hair-
pins had slightly different efficacy of knockdown, each resulted
in GRN levels equivalent with GRN levels in patients, which typi-
cally range between a 50% and 75% reduction (Finch et al.,
2009). Furthermore the cohort of genes differentially expressed
with both hairpins was highly significantly overlapping (see
below), providing further confidence in the robustness of the
results.
Given its role as a mitogen, we first explored GRN’s effects on
NHNP cells in their proliferative state. We found that GRN has
little effect on progenitors, as only six genes were differentially
expressed between the targeting and scrambled hairpin condi-Neutions (Table S1, Bayesian t test, p < 0.05, log ratio > 0.2). We
next investigated cell number and proliferation, observing no
change in cell number or in proliferation rate in the face of GRN
knockdown (Figure 2A). This is consistent with the absence of
an obvious developmental phenotype in GRN knockout mice
(Ahmed et al., 2010; Yin et al., 2010) and the phenotype of
patients with GRN mutations, who suffer loss of postmitotic
neurons after several decades of life.ron 71, 1030–1042, September 22, 2011 ª2011 Elsevier Inc. 1031
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Figure 2. Neuronal Cell Death Occurs in Differentiating NHNP Cells with GRN Knockdown
(A) GRNi cells demonstrate no difference in cell number or proliferation.
(B) GRNi cells demonstrate significantly increased pyknotic nuclei.
(C) There is a statistically significant increase in activated CASP3 staining in GRNi cells whether GRN is lost during differentiation (left) or postdifferentiation (right).
(D and E) There are significantly (p < 0.05) fewer TUJ1+ cells but similar number of GFAP+ cells (p = 0.50) in cells lacking GRN. Cells were only considered to be
TUJ1+ if they had a neuronal morphology. Asterisks indicate p% 0.05 and error bars are ± SEM (unpaired two-tailed Student’s t test, n = 3). See also Figure S3.
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studied the effects of GRN knockdown in nondividing, differenti-
ated hNPC cells. hNPCs were differentiated for four weeks in
the presence of doxycycline, which induced shRNA expression.
We confirmed cellular differentiation, first showing that nestin
staining 1 month postdifferentiation is lost (Figures S2A and
S2B). We then confirmed the upregulation of markers of early
neuronal differentiation and maturation. Differential expression
analysis showed clear upregulation of neuronal markers (Table
S1) such as DCX (p < 10E-12) and TUBB3 (also named Tuj1,
p < 1E-2), and also of glial markers such as GFAP (p < 5E-3) at
the RNA level andMAP2, TUJ1, and GFAP staining at the protein
level (Figures S2C–S2D). GO analysis provides a more global
view of the changes, yielding obvious enrichment in DE cate-
gories such as neuron differentiation, axonogenesis and neural
projection development, apoptosis, and regulation of cell size
(Table S1, EASE Score, p < 10E-6), further confirming neuronal
differentiation.
Given that the ultimate consequence of GRN insufficiency
(GRNi) in humans is neuronal death, we determined the effect
of GRN deficiency on neuronal survival. In GRNi neural progen-
itor cultures, we observed increased pyknotic nuclei (Figure 2B)1032 Neuron 71, 1030–1042, September 22, 2011 ª2011 Elsevier Increlative to the scrambled hairpin control condition, consistent
with increased cell death. To confirm this observation, we as-
sessed activated CASP3 staining, which confirmed the initial
observations of increasing apoptosis with GRN reduction (Fig-
ure 2C). To show that this apoptotic phenotype is not an artifact
of progenitor proliferation or differentiation state, we also
reduced GRN levels in differentiated cells via doxycycline appli-
cation after differentiation of the progenitors over a course of
3 weeks, so that there were no remaining mitotically active cells.
We saw a similar increase in CASP3 staining in this condition as
well (Figure 2C).
To determine whether GRN loss preferentially affects neurons
or glia, we performed immunostaining, observing loss of Tuj1+
positive cells, but similar numbers of GFAP+ cells, indicating
that subacute GRN loss leads to neuronal apoptosis (Figures
2D and 2E). Additionally, when inducing GRNi postdifferentia-
tion, GRNi cultures demonstrated fewer, but not statistically
significantly less MAP2 positive cells at a 6-week time point (Fig-
ure S3), further confirming that the loss of neurons is not due to
an effect on progenitor cell differentiation. Thus, GRN downregu-
lation in primary neuronal cells in vitro also leads to reduced
neuronal survival, as it does in vivo..
Gene Ontology P-value
Cell Death 0.001
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Figure 3. GO Analysis Uncovers the Wnt Signaling Pathway
(A) Gene ontology analysis was carried out using DAVID on the set of differentially expressed genes.
(B) qRT-PCR was performed on some of the important players in the Wnt pathway to verify these gene expression changes. The left two bars show expression
changes on array, and the right bar shows expression changes as measured by qPCR. qPCR was performed by comparing the second GRN hairpin versus the
scrambled hairpin.
(C) KEGG pathway for Wnt signaling, with differentially expressed genes during GRNi (p < 0.05) circled. Upregulated genes are colored red and downregulated
genes are colored green. See also Figure S4, Figure S5, and Table S2.
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the Wnt Pathway
We next assessed gene expression changes associated with
GRNi that might contribute to the apoptotic phenotype. We
took the union of the changes observed in both GRN hairpins
relative to the scrambled condition, so as to identify a conserva-
tive and highly robust group of 58 upregulated and 95 downregu-
lated genes (Bayesian t test, p < 0.005; Figure 1C and Table S3).
The intersection of differentially expressed genes between the
two hairpins is highly significant (hypergeometric probability of
10E-67). Furthermore, virtually all (>99%) of those identified in
these two independent experiments with different targeting hair-
pins were differentially expressed in the same direction relative
to control, a high degree of internal consistency. These data
provide evidence of robust alterations in gene expression specif-
ically caused by GRN loss.
As a first step in organizing and categorizing the function of the
differentially expressed genes with GRN loss, we conducted
gene ontology (GO) analysis using David (http://david.abcc.
ncifcrf.gov/) to determine enrichment of GO categories (Table
S2). Several potentially important observations emerged (Fig-
ure 3A), including cell death and apoptosis, consistent with the
cell death observed by GRN loss in differentiating neural progen-
itor cells. To further confirm these gene ontology categories, we
create a custom network via Ingenuity, in which the top network
is significant for cell death (Figure S4).
Notably, within the GO analysis there was only one KEGG
signaling pathway whose members were overrepresented with
GRN knockdown, the Wnt signaling pathway. Members of the
Wnt signaling pathway with significant alterations in expression
included: CD24, WNT1, SFRP1, NKD2, and the Wnt receptor
FZD2. Other Wnt genes that were nominally significant includeNeuGSK3B, PPP2R2B, APC2, and CER1. To provide independent
validation, gene expression changes of key Wnt signaling
pathway members are additionally validated by qRT-PCR (Fig-
ure 3B). These changes follow a clear pattern: genes that typi-
cally activate canonical Wnt signaling are upregulated (WNT1,
FZD2, APC2), whereas genes that normally inhibitWnt signaling
are downregulated (GSK3B, SFRP1, NKD2, CER1) (Figure 3C).
This indicates that an early consequence of GRN loss in vitro in
human neural cells is an increase in Wnt signaling components
that increases pathway activity. To test this prediction, we per-
formed a direct experimental assay ofWnt activity in this model
using the canonical LEF/TCF reporter (Experimental Proce-
dures). LEF/TCF signaling was increased in the GRN knockdown
condition (Figure S5), confirming that indeed Wnt signaling is
altered. Moreover, noncanonical Wnt signaling pathways AP1,
cJun, and NFAT assayed by the same reporter system (Experi-
mental Procedures; Figure S5) show no significant changes,
indicating that the alterations in Wnt signaling converge on the
canonical pathway.
WGCNA Highlights Cell Cycle, Ubiquitin,
and Wnt Signaling Pathways
Although the GO analysis points to several potential key alter-
ations in biological and molecular functions coupled with GRN
deficiency, GO analysis is considered only a first step, since
the function of many genes is not well-annotated. Recently, we
have shown that WGCNA (Zhang and Horvath, 2005) provides
a system level framework for the understanding of transcriptional
profiles in many distinct cellular and tissue contexts (Geschwind
and Konopka, 2009; Miller et al., 2008; Oldham et al., 2008;
Winden et al., 2009; Voineagu et al., 2011). WGCNA has the
power to reveal the underlying organization of the transcriptomeron 71, 1030–1042, September 22, 2011 ª2011 Elsevier Inc. 1033
Figure 4. WGCNA Analysis of GRN Deficiency in Cell Culture
WGCNA analysis (see Experimental Procedures) was carried out on the cell-culture data, and we chose to focus on two modules of importance: one containing
GRN, and on another that is most correlated with GRN knockdown samples. (A) Module eigengenes (ME) are computed from the first principle component of the
gene expression data to summarize the major trend in gene expression within each module. Samples are plotted along the x axis where each bar represents one
sample, and the value of the ME for each sample is displayed on the y axis. These plots show that these twomodules are specific to the samples containing GRN
knockdown. Genes in the green module are generally upregulated with GRN loss, whereas genes in the yellow module are downregulated. (B) The strongest
connections based on topological overlap are plotted for ease of analysis. This allows for easy visualization of highly connected genes within each module. See
also Figure S6, Table S3, and Table S4.
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hood sharing, which is defined based on coexpression relation-
ships. This facilitates the identification of modules of functionally
related, highly coexpressed genes, as well as the most central or
hub genes that are of prime importance to module function
(Geschwind and Konopka, 2009; Miller et al., 2008; Oldham
et al., 2008; Winden et al., 2009). We condense the gene expres-
sion pattern within a module to a ‘‘module eigengene’’ (ME)
which is a weighted summary of gene expression in the module
(Oldham et al., 2008). Correlation between the ME and a given
state, such as GRNi is indispensable as a metric to determine
how a module may be relevant to that state.1034 Neuron 71, 1030–1042, September 22, 2011 ª2011 Elsevier IncWe performed WGCNA (Experimental Procedures and
Supplemental Experimental Procedures) identifying 24modules,
five of which (correlation > 0.50, p < 0.05) were significantly
correlated with GRN knockdown (Table S3). Two of these
modules were of particular interest: the green module that con-
tained GRN and the yellow module whose module eigengene
was most correlated with GRN knockdown.
The green module contains 902 genes, and this module was
then further divided into submodules (Supplemental Experi-
mental Procedures). We focused on the submodule containing
GRN (Figures 4A and 4B, left). GO of this submodule, containing
167 genes, revealed that it is primarily comprised of genes.
Neuron
Pathways Dysregulated by Progranulin Deficiencyrelated to mitochondrial function (Table S5, EASE score p <
0.001), the majority of which decrease with GRN loss. Mitochon-
dria have been implicated as a pivotal organelle in many neuro-
degenerative diseases, including AD and PD (Morais and De
Strooper, 2010; Swerdlow, 2009). These data indicate that
alteration in mitochondrial function is a primary effect of GRN
deficiency in the CNS and support a role for mitochondrial
dysfunction in GRN-related FTD as well.
The keymodule that may represent a cellular response toGRN
loss is the yellow module, which contains 517 genes and was
most correlated with GRN deficiency. We observed that this
module contained a submodule with even higher correlation to
GRN deficiency, so we chose to analyze this submodule as it
represents the group of genes with highest correlation to GRNi
(Figures 4A and 4B, right). The yellow submodule contains 241
genes, and more than 95% of these 241 genes increase with
GRNi (Table S4). GO analysis of this module (Table S4) demon-
strated that it was enriched in the categories of ubiquitin-
mediated proteolysis (p < 0.03), Wnt signaling (p < 0.05), and
apoptosis (p < 0.02). Notable highly connected (‘‘hub’’) genes
in this module include Wnt signaling genes, such as FZD2, but
also upregulation of proapoptotic genes like CASP9 and
MGRN1, the latter a ubiquitin ligase whose depletion has been
shown to cause neurodegeneration (Chakrabarti and Hegde,
2009). Other Wnt signaling genes such as WNT1, CTNNBL1,
and VANGL2 are also highly connected within this yellow
module. Ubiquitin positive inclusions containing TDP-43 are a
hallmark of GRN positive FTD (Neumann et al., 2006), and
upregulated genes within this module that are related to this
pathway include the ubiquitin conjugating enzymes, UBE2C
and UBE2D3. To test for upregulation of ubiquitination within
this model we performed western blotting with an antipolyubi-
quitin polyclonal antibody, demonstrating a significant increase
in polyubiquitinated proteins with GRN knockdown (Figure S6).
The upregulation of these pathways here further confirms an
early increase in the ubiquitin protein stress pathways concom-
itant with GRN loss.
This analysis clearly connects GRN function to mitochondria
and protein degradation pathways, and places multiple mem-
bers of the Wnt signaling pathway in central roles downstream
of GRN deficiency. These network data also bolster the
suggestion, based on the initial analysis of differential expres-
sion, that Wnt signaling may be integral to GRN function and
regulation, as both a supervised analysis using differential ex-
pression and an unsupervised analysis using WGCNA highlight
Wnt signaling as a major pathway associated with GRN loss.
Gene Expression Related to Postmortem Human Brain
Next, we sought to extend these in vitro observations to in vivo
human data and provide independent validation of their rele-
vance to human FTD. Although in vitro derived expression data
have the power to demonstrate which expression changes
observed in brain are direct effects of GRN loss, and not post-
mortem confounders (Mirnics and Pevsner, 2004), the optimal
translational value lies in extending these observations to human
patient material (Karsten et al., 2006). In this framework, first we
determine causality in the absence of postmortem confounders
in vitro, and we then use the postmortem tissue to confirm theNeurelevance of the in vitro findings to human FTD pathophysiology
(Karsten et al., 2006).
We performed WGCNA on a data set provided by Chen-Plot-
kin et al. (2008) where microarrays were run on three brain
regions (cerebellum, hippocampus, and frontal cortex) from
three subject groups (controls, sporadic FTD, and GRN+ FTD).
Following quality control to remove technical outliers (Experi-
mental Procedures; Oldham et al., 2006), 52 arrays remained.
WGCNA identified 29 modules (Figure 5A), 14 of which were
related to brain region (e.g., cortex or cerebellum) (Oldham
et al., 2006), 8 were significantly correlated with GRN+ FTD
(correlation > 0.50, p < 0.05, Table 1), and 2 of which were signif-
icantly correlated with sporadic FTD (Table S5, Experimental
Procedures). Lastly, some modules are driven by individuals,
and may be related to factors such as cause of death or agonal
state, as has been previously reported (Oldham et al., 2008). The
eight modules whose ME is significantly correlated with GRN+
FTD show that there is a specific gene network associated
with GRN+ disease state. Given the similarity in pathology of
GRN+ and sporadic FTD, this is remarkable in showing that
despite the chronic inflammation and microgliosis present in
both forms of FTD, GRN loss produces a specific set of altered
gene networks that is preserved even late in disease (Figures
S7A–S7G). Of note, there is nearly total agreement between
theME correlations observed in two brain regions, hippocampus
and frontal cortex, consistent with the notion that the ME is
a robust measure, as has been previously demonstrated in
several settings (Konopka et al., 2009; Oldham et al., 2008;
Winden et al., 2009; Voineagu et al., 2011).
GO analysis of the GRN+ associated modules (Experimental
Procedures) revealed some pathways previously linked to neu-
rodegeneration, such as those relating to inflammation, mito-
chondria, synaptic transmission, neural development, and cell
loss. At the same time, other modules with significant correlation
to GRN+ disease status revealed unexpected GO categories,
such as myelination, gliogenesis, and protein kinase and
nucleotide binding (Table 1). These data complement the data
already provided in Chen-Plotkin et al. (2008), providing a
systems level framework in which to delineate the GRN+ FTD
molecular signature identified using differential expression anal-
ysis in the original study. WGCNA allows for separation of
distinct factors that may be related to GRN+ FTD, and facilitates
the focus on the gene expression changes most relevant to
disease pathogenesis.
The GRN Coexpression Module Implicates Apoptosis
and Wnt Signaling Alterations
To further explore the relationship of the genes identified in vitro
with GRN downregulation in vivo, we analyzed the GRN contain-
ing module, the blue module. The blue ME is highly specific to
GRN+ FTD affected brain regions (Figure 5B), indicating that
genes in this module are specifically upregulated in these brain
areas. GO analysis identifiedWnt signaling to be significantly en-
riched within this module (Table S6), including canonical Wnt
pathway transcription factors LEF1, TCF7L1, and TCF7L2. To
probe the genes most associated with chronic GRN deficiency
in vivo, we again examined the submodule containing GRN
within this larger module. Remarkably, this module is centeredron 71, 1030–1042, September 22, 2011 ª2011 Elsevier Inc. 1035
Figure 5. WGCNA Analysis on the Post-
mortem Brain Data Set
(A) Dendrogram showing relationship of topolog-
ical overlap of genes and their relation to modules,
which are color-coded below.
(B) First module eigengene is plotted of the
blue module, a measure of the general expression
of the genes in a given module. Violet samples
are controls, dark blue samples are FTD with GRN
mutations, and turquoise samples are sporadic
FTD.ThemodulecontainingGRN, thebluemodule,
is positively correlated with diseased GRN+ sam-
ples. This provides further evidence that GRN+
FTD has a distinct molecular phenotype even in
late-stage FTD as compared to sporadic FTD.
(C) A graphic depiction of the blue module using
VisANT (http://visant.bu.edu). For ease of viewing,
pairs of genes with the highest intramodular
topological overlap are depicted, with each link
corresponding to a TO value between the con-
nected nodes. This module is notable because it
contains GRN. Its hub genes are ANXA5 and
LRP10, indicating that this module is likely related
to apoptosis and Wnt signaling. See also Fig-
ure S7, Table S5, and Table S6.
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ure 5C): Annexin-V (ANXA5), a known mediator of apoptosis
(Vermes et al., 1995), and LRP10, a newly discovered inhibitor
of the canonical Wnt signaling pathway (Jeong et al., 2010).
This module also contains FZD2, which is upregulated and nega-
tively correlated with GRN levels in vivo, consistent with the
in vitro data. Analysis of these human brain samples revealed
that FZD2 is significantly upregulated only in frontal cortex of
GRN+ FTD samples, underscoring its potential role in disease
pathogenesis.1036 Neuron 71, 1030–1042, September 22, 2011 ª2011 Elsevier Inc.Target Validation in Mouse
The upregulation of multipleWnt pathway
activating components and downregula-
tion of negative regulators both in vitro
and in vivo showed a remarkable degree
of consistency. These data not only
support the relevance of theWnt pathway
changes observed in cell-culture and
in human FTD in vivo, but conversely
indicate which of the changes observed
in brain are a direct effect of GRN
loss, and are not due to postmortem
confounders, such as a change in cell
composition (due to inflammation or cell
loss) during the neurodegenerative
process. We were particularly intrigued
by the consistent upregulation of FZD2,
since it is one of the most proximal
pathway members, acting as a Wnt
receptor (Chan et al., 1992; Slusarski
et al., 1997). To follow Fzd2 in vivo at
a time prior to neuropathological alter-
ations or overt neurodegeneration, weanalyzed independent gene expression data from cerebellum,
cortex, and hippocampus of 6-week-old GRN knockout mice,
at a time point before overt cell loss or neuropathology. This
analysis demonstrated only 25 differentially expressed genes
in cortex (Table S7, p < 0.005, log ratio > 0.2) and no significantly
enriched KEGG pathways. A comparison to the human data
showed that human GRNi stem cells have a greater number of
genes in common with patient GRN+ brain than the knockout
mice at this time point (Figure 6A). But, of the few changes
observed in mice, Fzd2 upregulation is one of the most
Table 1. Modules Specific To GRN+ FTD Disease State
Module Correlation p Value Top Three Hub Genes by Kme Notable Gene Ontology (p Value)
Blue 0.66 7.95E-08 PARP4, FOXO1, RIN2 Wnt signaling pathway (<0.02), apoptosis (<0.02),
UbI conjugation (<0.005)
Cyan 0.53 4.66E-05 DNM1L, SYNJ1, NBEA Protein kinase (<10e-4), nucleotide binding (<0.002)
Dark olive green 0.65 1.60E-07 NAP1L3, AAK1, CAMTA1 Synaptic transmission (<10e-4), calcium ion binding (<0.01)
Green 0.56 1.51E-05 BSCL2, ACOT7, GNG3 Oxidative phosphorylation (<10e-18), mitochondria (<10e-15)
Light green 0.58 7.86E-06 PARP12, XAF1, SP100 Antiviral defense (<10e-17), immune response (<10e-9)
Orange 0.52 6.88E-05 C1QA, HCLS1, VSIG4 Response to wounding (<10e-21), immune response (<10e-20)
Steel blue 0.67 7.31E-08 FRMD4B, PIP4K2A, RASGRP3 Myelination (<10e-7), gliogenesis (<0.003)
Tan 0.60 2.60E-06 NSF, GLRB, AAK1 Nucleus (<3e-7), RNA splicing (<3e-5)
Correlation of the first module eigengene with diseased state is listed here. This table characterizes the modules by gene ontology, listing the gene
ontology category that is most characteristic of the module in question, and by top three connected genes according to their Kme, which connotes
the gene’s correlation with the module eigengene. See also Table S6.
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regions (Figure 6B). Fzd2 is also the second most upregulated
gene in cortex (Table S7) and it is upregulated in proportion to
GRN loss; Grn / mice have twice the Fzd2 increase as the
Grn +/ mice.
In mouse, Fzd2 remains upregulated at 6 and 9 months of age
(Figure 6C). But far more gene expression changes are detected
at these later ages, consistent with progression of the disease
(Table S7, 1203 and 813 genes, respectively, Bayesian t test
p < 0.05, log ratio > 0.2). At 9 months ‘‘lysosome’’ is the most
statistically significant gene ontology category, which is notable
because progranulin is endocytosed and delivered to lysosomes
by sortilin (Hu et al., 2010). Additionally, at 6 and 9 months,
changes in the Wnt signaling pathway become enriched in
cortex of Grn / mice (Table S8, p < 0.05). These mouse
data confirm that Fzd2 is upregulated with GRN loss, but that it
is one of the earliest features of GRN deficiency, confirming
the human data that it is not an in vitro artifact, or the result of
chronic degenerative or postmortem changes.
Experimental Validation of FZD2 In Vitro
Given the role of both the canonical and noncanonical Wnt
signaling pathway in cell death and survival in many contexts
from cancer to the nervous system, we set out to provide a proof
of principle experimental test of our analyses. Since FZD2 is
aWnt receptor and its expression showed early and robust up-
regulation with GRN knockdown, we sought to manipulate FZD2
expression in vitro (Figure S8), and to test one of two models
based on our data. The first is that FZD2 upregulation reflects
a protective or compensatory response, and the second that it
is part of the neurodegenerative process. In the first case, knock-
ing down FZD2 would be proapoptotic and in the second knock-
ing down FZD2 would be protective. FZD2 deficient differenti-
ating neuronal progenitors (Experimental Procedures; Figures
6D and 6F and Figure S7) had fewer total cells (Figure 6E) relative
to the control condition and demonstrated an increase in acti-
vated CASP3 staining, indicating apoptotic cell death. Dual
FZD2/GRN knockdown cells demonstrated similar numbers of
apoptotic cells relative to FZD2 knockdown alone (Figure 6D),
suggesting that upregulation of FZD2 is directly downstream of
GRN downregulation, since there was no additive effect.NeuWe next verified that upregulation of FZD2 increases cell
survival in the context of GRN loss in postdifferentiated, nonpro-
liferating GRNi cells that subsequently overexpress FZD2. Upre-
gulation of FZD2 in these GRNi cells increases total cell number
(Figure 7A), and decreases cell death (Figure 7B). Overexpres-
sion of FZD2 does not cause an increase in proliferation as
measured by PCNA immunoblotting (Figure 7C) and by brdU
immunocytochemistry (Figure 7D), indicating that this is not via
an effect on proliferation, but rather cell survival. The induction
of cell death by FZD2 downregulation suggests that the
observed consistent upregulation of FZD2 in neurons in vitro
and in vivo in patient brain reflects a potential neuroprotective
response to GRN loss.
DISCUSSION
The present study was designed to identify the systems-level
changes that accompany GRN reduction in human neurons.
Initially, we examined the effects of progranulin deficiency in
human fetal neural progenitors, a well-controlled in vitro model
of GRN-haploinsufficiency. An important strength of this model
is that it avoids potential confounding effects, such as chronic
inflammation, that plague postmortem studies of dementia.
Using this model, we demonstrate that progranulin deficiency
selectively compromises neuronal survival and engages the
canonical Wnt signaling pathway, the latter by way of both
gene expression and a direct measure of signaling activity. The
canonical Wnt signaling pathway is classically understood to
increase cell survival, which is likely its role here in the context
of GRN loss. Moreover, this association with Wnt is robustly
preserved in the higher-order network architecture of transcrip-
tional changes in the frontal cortex of FTD patients with
progranulin mutations, and in Grn/mouse, proving its in vivo
relevance. These data show that the combination of in vitro data,
which can prove causality, and in vivo data, which confirms rele-
vance to human disease, is a powerful approach.
Given the potential divergence ofmouse and human transcrip-
tional networks, this parallel between mouse and human
systems was not a forgone conclusion (Miller et al., 2010), but
provides another key line of evidence supporting the role of
Wnt signaling and FZD2. Since these changes are evident wellron 71, 1030–1042, September 22, 2011 ª2011 Elsevier Inc. 1037
A B
C
E F
D
Figure 6. FZD2 Upregulation Occurs Early after GRN Reduction
(A) Overlap of differential expression between NHNP cells, mouse, and FTD GRN+ patients, showing that there is greater overlap between NHNP cells and
affected patient brain (p < 0.05, Bayesian t test).
(B) Fzd2 is upregulated in proportion to Grn gene dosage in mouse brain. (n = 5, unpaired Student’s t test, p < 0.05). Plots depict log fold change of Fzd2.
(C) Differential expression of FZD2 in GRN knockout mice at 6 weeks, 6 months, and 9 months (n = 3–5, unpaired Student’s t test, p < 0.05). Plots depict fold
change of Fzd2 in Grn / versus Grn +/+ mice.
(D and E) Differentiated NHNP cells in culture with FZD2 knockdown demonstrate a significantly larger percentage (n = 3, error bars ± SEM, unpaired Student’s
t test, p < 0.05) of (D) dying cells and (E) lower total cell number. However, dual FZD2/GRN knockdown demonstrate similar numbers of apoptotic cells relative to
FZD2 alone (D).
(F) Staining showing increased activated CASP3 staining (green) in FZD2 knockdown (right) as opposed to control (left). Numerous pyknotic nuclei are evident
in FZD2 knockdown cells as well. See also Figure S8, Table S7, and Table S8.
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overt neurodegeneration, these data suggest that FZD2 may
prove useful as an early biomarker of disease progression. We
show that loss of FZD2 is sufficient to cause cell death, but
gain of FZD2 increases cell survival, suggesting that the upregu-
lation of FZD2 is likely neuroprotective, consistent with its role
as a growth factor. Together these data suggest that FZD2 plays
a compensatory, potentially neuroprotective role in GRN defi-
cient cells.1038 Neuron 71, 1030–1042, September 22, 2011 ª2011 Elsevier IncDual Role of Wnt Signaling in Neurodegeneration
A general association exists between Wnt-Frizzled signaling and
cell survival in many cellular systems (Chen et al., 2001; Rawal
et al., 2009). A more specific link between aberrantWnt signaling
and FTD or Alzheimer’s disease (AD) was first postulated be-
cause the canonical messenger GSK-3b is responsible for phos-
phorylation of MAPT, an initial step in the formation of neurofibril-
lary tangles (Behrens et al., 2009; Boonen et al., 2009; Jackson
et al., 2002; Karsten et al., 2006). Subsequently, animal models.
A B
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Figure 7. FZD2 Upregulation Is Neuroprotective
(A and B) GRNi cells were differentiated and after 4 weeks, and subsequently
FZD2 was overexpressed for 4 weeks concurrently with GRN loss. The cells
overexpressing demonstrate (A) greater cell number, and (B) fewer dying cells,
suggesting overexpression of FZD2 is neuroprotective in the context of GRN
loss (n = 3, error bars ± SEM, unpaired two-tailed Student’s t test, p < 0.05).
(C and D) In normal NHNP cells, FZD2 overexpression does not cause
a change in proliferation as measured by (C) PCNA immunoblotting or by (D)
brdU immunostaining.
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Pathways Dysregulated by Progranulin Deficiencyof AD and FTD further implicated Wnt signaling in the etiology
of neurodegeneration by showing (1) disease causing mutated
Presenilin alters Wnt signaling, increasing apoptosis (Soriano
et al., 2001; Weihl et al., 1999); and (2) Ab can both directly and
indirectly interfere with canonical Wnt signaling and that this
interference compromises neuronal survival (Caricasole et al.,
2004; Scali et al., 2006). Wnt signaling therefore may provide
a bridge between neurodevelopment and neurodegeneration
(Geschwind and Miller, 2001; Jackson et al., 2002).
Implications for Disease Pathophysiology
It is still an open question as to whether loss of GRN causes FTD
pathology through a cell autonomous or noncell autonomous
mechanism. Loss of GRN may increase neuronal vulnerability,
conferring an intrinsic property in which neurodegeneration is
more likely. Alternatively, microglia lacking GRN may become
hyperactive, creating a poor extrinsic environment that leads to
neuronal death. This is a complex issue because GRN is a
secreted protein, the form of GRN that is clinically relevant to
FTD is currently unknown, and GRN transcripts are decreased
in blood, but are paradoxically increased inGRN+diseased brain
(Chen-Plotkin et al., 2010).
The data that we present here, in which GRN loss is sufficient
to produce cell death in the absence of microglia, shows that
neuronal GRN deficiency is sufficient to significantly reduce
neuronal survival, a finding important for potential therapeutics
development. While these data argue that GRN loss can indeed
increase neuronal vulnerability, they do not preclude the com-
pounding involvement of microglia in the pathophysiology of
FTD in patient brain, which may form a vicious cycle (Pickford
et al., 2011; Yin et al., 2010).NeuFZD2 and Noncanonical Wnt Signaling and Clinical
Significance
Here we provide data from multiple systems showing that FZD2
expression increases with GRN loss. We then performed a proof
of principle experiment, indicating that this increase may be
protective. Classically, signaling through the FZD2 receptor acti-
vates the noncanonical Wnt signaling pathway (Oishi et al.,
2003). This suggests that modulation of this pathway may have
therapeutic relevance; previous work has shown that noncanon-
ical Wnt agonists can be protective in other forms of dementia
(Inestrosa and Toledo, 2008). As opposed to canonical Wnt
signaling, which has already been established as a major player
in neurodegeneration (Hooper et al., 2008; Toledo et al., 2008),
these data indicate a role for Wnt signaling independent of
GSK-3b and b-catenin in neurodegenerative pathology. Addi-
tionally, FZD2 is the initial change that precedes alterations in
otherWnt pathwaymembers inmouse in vivo at stages well prior
to neurodegeneration or neuronal loss. Thus, FZD2 represents
a primary target in that it is a consistent and early upregulated
gene in the context of GRN loss.
Neuroprotection via upregulation of FZD2 is consistent with
the characteristically understood role of Wnt signaling as pro-
growth and antiapoptosis in multiple systems (Chen et al.,
2001; Lie et al., 2005; Willert et al., 2003; You et al., 2002).
Further, disease onset and rate of progression may correlate
with endogenous baseline activity of neuroprotection provided
by theWnt signaling pathway (De Ferrari et al., 2007). Themanip-
ulation of FZD2 and other members of its pathway is thus
a potential therapeutic target worthy of further investigation.
Thus, it is reasonable to consider that small molecule agonists
of the noncanonical Wnt signaling pathway are potential new
targets in GRN+ FTD. Since Wnt signaling is cell context and
receptor dependent, gaining a full understanding of the other
players in the pathway that may interact with FZD2 is crucial.
This work provides the impetus for further in depth exploration
of Wnt signaling in FTD and suggests the potential use of Wnt
agonists to assuage the neurodegenerative phenotype of
GRN+ FTD.EXPERIMENTAL PROCEDURES
Microarray Data and WGCNA Analysis
Human neural progenitor cells were infected, selected with puromycin, and
differentiated for 4 weeks. Microarray analysis was performed as reported
previously (Konopka et al., 2009). See Supplemental Experimental Procedures
for details.
Postmortem expression data from FTD patients and controls was obtained
from (Chen-Plotkin et al., 2008) (GSE13162:GSM329660-GSM329715).
Network analysis was performed using previously publishedmethods (Oldham
et al., 2006, 2008; Winden et al., 2009). Gene ontology (GO) analysis was per-
formed using the DAVID functional annotation tool (http://david.abcc.ncifcrf.
gov/) (Huang et al., 2009a, 2009b). See Supplemental Experimental Proce-
dures for more details.
Plasmids
Initially, the pLCIR plasmid was used containing CAG promoter, chosen
because of its robust expression in neurons, driving shRNA against GRN.
The control was a GFP hairpin used previously (Matsuda and Cepko, 2007).
To knock down GRN in an inducible system, pTRIPZ vector was purchased
from Open Biosystems (Huntsville, AL). Their scrambled pTRIPZ vector wasron 71, 1030–1042, September 22, 2011 ª2011 Elsevier Inc. 1039
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The sequence of the other GRN hairpin was obtained from (Zhang et al., 2007),
and was cloned into TRIPZ using the PCR shagging protocol (http://katahdin.
cshl.org:9331/RNAi/html/rnai.html). FZD2 knockdown was accomplished by
purchasing FZD2 hairpins in vector pLKO (Open Biosystems), and pLUIP
was used to overexpress FZD2, containing a U6 promoter driving expression
of FZD2 with PuroR driven by an IRES. More detailed material on plasmids and
sequences can be found in Supplemental Experimental Procedures.
Cell Lines and Cell Culture
Human neural progenitor cells (NHNPs) were generated from a 17-week gesta-
tion aborted female fetus. Tissue was homogenized, plated, and cultured as
previously described (Svendsen et al., 1998; Wexler et al., 2008), and further
elaborated in the Supplemental Experimental Procedures.
Antibodies, Reagents, and Assays
The following antibodies were used for either immunoblotting (IB) or immuno-
fluorescence (IF): anti-GRN (rabbit polyclonal, Invitrogen; 1:500 IB), anti-
b-actin (mouse monoclonal, Sigma ;1:50,000 IB), anti-HA (mouse monoclonal,
Covance; 1:2,000 IB), antipolyubiquitinated conjugates (mouse monoclonal,
Biomol, 1:2000 IB), anti-PCNA (rabbit polyclonal, Santa Cruz Biotechnology,
1:200), anticleaved-caspase-3 (rabbit polyclonal, Cell Signaling; 1:1,000 IF),
anti-GFAP (goat polyclonal, Abcam; 1:1,000 IF), anti-TUJ1 (rabbit polyclonal,
Millipore, 1:1,000 IF), anti-BrdU (rat monoclonal, Abcam, 1:1,000 IF), goat
anti-rabbit horseradish peroxidase (Cell Signaling; 1:2,000), goat anti-mouse
horseradish peroxidase (Sigma; 1:5,000), goat anti-rat Alexa Fluor 488
(1:1,1000), donkey anti-rabbit Alexa Fluor 488 (1:1,1000), donkey anti-mouse
Alexa Fluor 647 (1:1,000), donkey anti-rabbit Alexa Fluor 633 (1:1,000).
Immunocytochemistry (ICC)
Cells were fixed using 4% paraformaldehyde (Sigma). Cells were permeabi-
lized by incubating with 0.5% Triton-X for 10 min. Antigen retrieval for brdU
staining was performed using 100 units/mL of DNase I (Worthington, Lake-
wood, NJ) supplemented with 1 mM MgCl2. Cells were blocked for 30 min in
3% donkey serum, 0.2% Triton-X, diluted in TBS. Primary antibodies were
diluted in blocking buffer and were incubated overnight at 4C. Secondary
antibodies were incubated for 1 hr at room temperature in the dark. All cells
were counterstained with DAPI (1:5000 diluted in TBS) and coverslips were
mounted using ProLong Antifade (Invitrogen). Three biological replicates
were performed per experiment. Six high-power fields were counted per
coverslip, except in relation to FZD2 manipulation experiments, in which four
high-power fields were counted per coverslip.
Wnt Activity Assays
Dual GFP/luciferase reporters were purchased from System Biosciences
(Mountain View, CA) for TCF/LEF, AP1, cJun, and NFAT. Lentivirus was
produced to infect proliferating NHNP cells already harboring targeting and
nontargeting GRN hairpins, producing eight different transduced lines. Six bio-
logical replicates of each line were induced for 1 week with doxycycline and
compared to its uninduced counterpart. GFP fluorescence was assessed
using a Plate Reader (BioTek) to determine relative activity for each reporter
in each cell type.
Mice
Progranulin knockout mice were created as reported previously (Kao et al.,
2011). The mice used for the microarray study were backcrossed into the
C57BL/6 strain twice.
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